Last updated 39 days ago
Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies
35 patients around the world
Available in Mexico
This is an open-label study to provide continued access to treatment for eligible
participants who continue to derive clinical benefit as determined by the investigator
from study intervention(s) in a Pfizer-sponsored palbociclib clinical study (Parent
Study)
Pfizer
1Research sites
35Patients around the world
This study is for people with
Head and neck cancer
Breast Cancer
Requirements for the patient
From 18 Years
All Gender
Medical requirements
- Any participant who is receiving study treatment and deriving clinical benefit as determined by the investigator in a Pfizer-sponsored palbociclib Parent StudyParticipants must agree to follow the reproductive criteriaParticipants who are willing and able to comply with all scheduled visits, treatment plans, and other study proceduresCapable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent document and protocol
- Any medical reason that, in the opinion of the investigator or sponsor, precludes the participant from inclusion in the study
Sites
Universidad Autónoma de Nuevo León, Hospital Universitario Dr. José Eleuterio González
Recruiting
SponsorPfizer
Study typeInterventional
Conditions
Head and neck cancerBreast Cancer
Requirements
From 18 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT05226871
